Nyxoah (NASDAQ:NYXH) versus Alpha Tau Medical (NASDAQ:DRTS) Head-To-Head Contrast

Alpha Tau Medical (NASDAQ:DRTS) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares Alpha Tau Medical and Nyxoah”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$29.16 million	($0.43)	-5.40
Nyxoah	$5.08 million	39.26	-$46.77 million	($1.87)	-4.28

Alpha Tau Medical has higher earnings, but lower revenue than Nyxoah. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alpha Tau Medical and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-38.62%	-29.89%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Institutional and Insider Ownership

2.7% of Alpha Tau Medical shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Alpha Tau Medical has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Alpha Tau Medical and Nyxoah, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	0	0	3	0	3.00
Nyxoah	0	0	5	0	3.00

Alpha Tau Medical presently has a consensus target price of $8.00, suggesting a potential upside of 244.83%. Nyxoah has a consensus target price of $17.00, suggesting a potential upside of 112.50%. Given Alpha Tau Medical’s higher possible upside, research analysts clearly believe Alpha Tau Medical is more favorable than Nyxoah.

Summary

Alpha Tau Medical beats Nyxoah on 8 of the 12 factors compared between the two stocks.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.